NeuroJunct Bio Announces Nearly RMB 100 Million Series A Financing to Advance First-in-Class In Vivo Reprogramming Therapy NRG-103

NEUREGEN Announces Completion of Series A Financing RoundNEUREGEN has announced the completion of its Series A financing round. This round was led by Wuhan Optics Valley Sci-Tech Innovation Industry Investment Fund Partnership (Limited Partnership), with participation from Zhuhai Hengqin SoftBank Xinchuang Equity Investment Management Enterprise (Limited Partnership). The funds will be primarily used to advance core pipeline clinical trials, preclinical research and development for other pipelines, and the continuous iteration of the in-situ transdifferentiation technology platform. Including the previously completed Pre-A+ round (with follow-on investments from existing shareholders Linchuang Sinan and Shanghai Science & Technology Investment Corporation), NEUREGEN has raised nearly 100 million RMB in 2025, strongly supporting the company’s strategy of "steady progress while safely accelerating into the fast lane."

NEUREGEN, centered around its original and globally leading in situ transdifferentiation (in vivo cell reprogramming) technology platform, has established multiple innovative product pipelines in significant unmet clinical needs areas such as oncology, ophthalmology, and neurodegenerative diseases. Among these, NRG-103, a treatment for high-grade glioblastoma, has successively received clinical trial approval (IND) from the Center for Drug Evaluation (CDE) of the China National Medical Products Administration, orphan drug designation (ODD) from the U.S. Food and Drug Administration (FDA), and IND approval. It has now entered Phase I clinical trials in China and is a genuinely First-in-Class (FIC) drug originating from Chinese science.